// App-Quantinova.ai

174 : Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Manish Kohli

Principal Investigators

  • Hugues Sicotte

  • Joseph Cernigliaro

  • Fernando Quevedo

  • Brian Addis Costello

  • Henry Clement Pitot

  • Timothy J. Moynihan

  • Thai Huu Ho

  • Roxana Stefania Dronca

  • Alan Haruo Bryce

  • Jeanette Eckel-Passow

  • Winston Tan

  • Kevin Wu

  • Scott Dehm

  • Patrick W Eiken

  • Rafael E. Jimenez

  • Liewei Wang

  • Rui Qin

  • Rachel Carlson

Medical Centers

  • University of Minnesota, Minneapolis, MN

  • Mayo Clinic, Rochester, MN, Rochester, MNMayo Clinic, Jacksonville, FL, Jacksonville, FLDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, Rochester, MN

  • Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

  • Mayo Clinic Scottsdale, Scottsdale, AZ

  • Department of Urology, Mayo Clinic, Rochester, MN, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor

  • Androgen receptor variant 7

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved